CA2888445A1 - Methods for making conjugates from disulfide-containing proteins - Google Patents

Methods for making conjugates from disulfide-containing proteins Download PDF

Info

Publication number
CA2888445A1
CA2888445A1 CA2888445A CA2888445A CA2888445A1 CA 2888445 A1 CA2888445 A1 CA 2888445A1 CA 2888445 A CA2888445 A CA 2888445A CA 2888445 A CA2888445 A CA 2888445A CA 2888445 A1 CA2888445 A1 CA 2888445A1
Authority
CA
Canada
Prior art keywords
protein
payload
conjugate
functionalized
disulfide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2888445A
Other languages
English (en)
French (fr)
Inventor
Qi-Ying Hu
Hidetomo Imase
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CA2888445A1 publication Critical patent/CA2888445A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F5/00—Orthopaedic methods or devices for non-surgical treatment of bones or joints; Nursing devices ; Anti-rape devices
    • A61F5/0003—Apparatus for the treatment of obesity; Anti-eating devices
    • A61F5/0006—Diet or mouth appliances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61C—DENTISTRY; APPARATUS OR METHODS FOR ORAL OR DENTAL HYGIENE
    • A61C5/00—Filling or capping teeth
    • A61C5/90—Oral protectors for use during treatment, e.g. lip or mouth protectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F5/00—Orthopaedic methods or devices for non-surgical treatment of bones or joints; Nursing devices ; Anti-rape devices
    • A61F5/56—Devices for preventing snoring
    • A61F5/566—Intra-oral devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Nursing (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Dentistry (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Dental Tools And Instruments Or Auxiliary Dental Instruments (AREA)
CA2888445A 2012-11-30 2013-11-26 Methods for making conjugates from disulfide-containing proteins Abandoned CA2888445A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261731852P 2012-11-30 2012-11-30
US61/731,852 2012-11-30
PCT/IB2013/060427 WO2014083505A1 (en) 2012-11-30 2013-11-26 Methods for making conjugates from disulfide-containing proteins

Publications (1)

Publication Number Publication Date
CA2888445A1 true CA2888445A1 (en) 2014-06-05

Family

ID=49726841

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2888445A Abandoned CA2888445A1 (en) 2012-11-30 2013-11-26 Methods for making conjugates from disulfide-containing proteins

Country Status (13)

Country Link
US (3) US10022256B2 (enExample)
EP (1) EP2925368B1 (enExample)
JP (1) JP6408480B2 (enExample)
KR (1) KR20150090081A (enExample)
CN (1) CN104853781B (enExample)
AU (1) AU2013350802B2 (enExample)
BR (1) BR112015011317A2 (enExample)
CA (1) CA2888445A1 (enExample)
EA (1) EA201591049A1 (enExample)
ES (1) ES2732574T3 (enExample)
IN (1) IN2015DN02913A (enExample)
MX (1) MX2015006868A (enExample)
WO (1) WO2014083505A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013350802B2 (en) 2012-11-30 2016-07-14 Novartis Ag Methods for making conjugates from disulfide-containing proteins
EP3024847A1 (en) 2013-07-25 2016-06-01 Novartis AG Disulfide cyclic polypeptides for the treatment of heart failure
WO2015013169A2 (en) * 2013-07-25 2015-01-29 Novartis Ag Bioconjugates of synthetic apelin polypeptides
WO2015013165A1 (en) * 2013-07-25 2015-01-29 Novartis Ag Cyclic apelin derivatives for the treatment of heart failure
EP3024845A1 (en) * 2013-07-25 2016-06-01 Novartis AG Cyclic polypeptides for the treatment of heart failure
ES2729643T3 (es) * 2013-11-26 2019-11-05 Novartis Ag Métodos para la conjugación de oxima con polipéptidos modificados con cetona
US20150182373A1 (en) * 2014-01-02 2015-07-02 DMD Todd D. Morgan Oral Exercise Appliance
JP6721572B2 (ja) * 2014-05-23 2020-07-15 ノバルティス アーゲー ジスルフィド含有タンパク質からコンジュゲートを作製するための方法
US10588980B2 (en) * 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
US20190194315A1 (en) 2015-06-17 2019-06-27 Novartis Ag Antibody drug conjugates
EP3310373A4 (en) 2015-06-22 2019-02-13 University of Utah Research Foundation Thiol-ene based peptide stapling and uses thereof
CR20180229A (es) * 2015-10-29 2018-08-24 Novartis Ag Conjugados de anticuerpos que comprenden un agonista del receptor tipo toll
CN109641051A (zh) * 2016-06-17 2019-04-16 美真达治疗公司 用于耗尽细胞的组合物和方法
US11034720B2 (en) 2016-07-17 2021-06-15 University Of Utah Research Foundation Thiol-yne based peptide stapling and uses thereof
AR113224A1 (es) 2017-04-28 2020-02-19 Novartis Ag Conjugados de anticuerpo que comprenden un agonista de sting
AU2018374283B2 (en) 2017-11-29 2025-09-18 Magenta Therapeutics, Inc. Compositions and methods for the depletion of CD5+ cells
WO2020089815A1 (en) 2018-10-31 2020-05-07 Novartis Ag Antibody conjugates comprising sting agonist
SG11202106370WA (en) 2019-01-16 2021-07-29 Regeneron Pharma Method and system of identifying and quantifying antibody fragmentation
FR3096259B1 (fr) * 2019-05-20 2023-12-15 Mc Saf conjugués anticorps-médicament et leur utilisation en thérapie
AU2020279979A1 (en) 2019-05-20 2021-11-25 Les Laboratoires Servier Mcl-1 inhibitor antibody-drug conjugates and methods of use
CA3140063A1 (en) 2019-05-20 2020-11-26 Novartis Ag Antibody drug conjugates having linkers comprising hydrophilic groups
CN116710138A (zh) * 2020-11-09 2023-09-05 国立大学法人鹿儿岛大学 肽交联剂以及通过该交联剂交联的交联肽
US20240391950A1 (en) * 2020-11-09 2024-11-28 Kagoshima University Peptide crosslinking agent and crosslinked peptide which is crosslinked using said crosslinking agent
WO2023201181A2 (en) * 2022-04-15 2023-10-19 Jeffrey Goldberg Hunger satiating dental appliance
EP4676540A1 (en) 2023-03-10 2026-01-14 Novartis AG Panras inhibitor antibody-drug conjugates and methods of use thereof
AR134424A1 (es) 2023-11-22 2026-01-14 Novartis Ag Conjugados de anticuerpo anti-cd7-fármaco y métodos de uso de los mismos

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6239110B1 (en) 1990-02-22 2001-05-29 W.R. Grace & Co. -Conn. Synthetic analogs of thrombospondin and therapeutic use thereof
WO1999013062A1 (en) 1997-09-09 1999-03-18 Nycomed Imaging As Factors vii fragments and analogs thereof and their use in the treatment of blood clotting disorders
WO1999013063A1 (en) 1997-09-09 1999-03-18 Nycomed Imaging As Factor vii fragments and analogs thereof and their use in the treatment of blood clottng disorders
GB0316294D0 (en) * 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
US8673848B2 (en) 2012-01-27 2014-03-18 Novartis Ag Synthetic apelin mimetics for the treatment of heart failure
HRP20110404T1 (hr) * 2005-11-08 2011-08-31 Ambrx Ubrzivači za modifikaciju ne-prirodnih aminokiselina i polipeptida ne-prirodnih aminokiselina
WO2008157380A2 (en) 2007-06-15 2008-12-24 Adherex Technologies Inc. Chemically modified cyclic peptides containing cell adhesion recognition (car) sequences and uses therefor
JP6074574B2 (ja) * 2008-02-05 2017-02-08 バイシクル セラピューティクス リミテッド 方法及び組成物
US20110172126A1 (en) 2008-09-03 2011-07-14 Xenome Ltd Libraries of peptide conjugates and methods for making them
DK2889624T3 (en) 2009-08-10 2018-12-10 Ucl Business Plc Reversible covalent bonding of functional molecules
SG11201502757QA (en) 2012-10-09 2015-05-28 Igenica Biotherapeutics Inc Anti-c16orf54 antibodies and methods of use thereof
WO2014078623A2 (en) 2012-11-15 2014-05-22 Brandeis University Tethering cysteine residues using cyclic disulfides
AU2013350802B2 (en) 2012-11-30 2016-07-14 Novartis Ag Methods for making conjugates from disulfide-containing proteins
ES2729643T3 (es) 2013-11-26 2019-11-05 Novartis Ag Métodos para la conjugación de oxima con polipéptidos modificados con cetona

Also Published As

Publication number Publication date
JP2015537045A (ja) 2015-12-24
CN104853781A (zh) 2015-08-19
EA201591049A1 (ru) 2015-09-30
CN104853781B (zh) 2017-10-24
US11311400B2 (en) 2022-04-26
US10667935B2 (en) 2020-06-02
IN2015DN02913A (enExample) 2015-09-18
BR112015011317A2 (pt) 2017-07-11
US20200253768A1 (en) 2020-08-13
JP6408480B2 (ja) 2018-10-17
WO2014083505A1 (en) 2014-06-05
US10022256B2 (en) 2018-07-17
KR20150090081A (ko) 2015-08-05
US20190038444A1 (en) 2019-02-07
ES2732574T3 (es) 2019-11-25
AU2013350802B2 (en) 2016-07-14
AU2013350802A1 (en) 2015-04-09
MX2015006868A (es) 2015-10-05
EP2925368A1 (en) 2015-10-07
EP2925368B1 (en) 2019-03-27
US20150290009A1 (en) 2015-10-15

Similar Documents

Publication Publication Date Title
US11311400B2 (en) Methods for making conjugates from disulfide-containing proteins
EP3074048B1 (en) Methods for oxime conjugation to ketone-modified polypeptides
EP3145552B1 (en) Methods for making conjugates from disulfide-containing proteins
EP3668871A1 (en) 6-amino-7,9-dihydro-8h-purin-8-one derivatives as immunostimulant toll-like receptor 7 (tlr7) agonists
GB2529356A (en) Novel linker and preparation method thereof
JP7228571B2 (ja) 免疫刺激因子トル様受容体７（ｔｌｒ７）アゴニストとしての６－アミノ―７，９－ジヒドロ－８ｈ－プリン－８－オン誘導体
AU2022375755B2 (en) Pyridazinedione-based heterobicyclic covalent linkers and methods and applications thereof
CN107106702A (zh) 使用亲和树脂合成adc的方法

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20191126